Gujarat Kidney And Super Speciality Limited (GKSL) — Announcement | 5 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Company clarified delayed filing penalties and XBRL correction
💡 Investor Takeaway
Shareholders should note the company promptly addressed regulatory filing issues without material financial impact.

Gujarat Kidney and Super Speciality Limited (GKSL) clarified to the NSE that it paid penalties for delayed financial results submission and corrected an inadvertent mismatch in consolidated cash flow figures within its XBRL filing, reaffirming compliance with SEBI LODR regulations.

📄 View Original Announcement (PDF)

About Gujarat Kidney And Super Speciality Limited (GKSL)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹1,280.41 Cr P/E: 66.0 ROE: 64.5% ROCE: 77.4%

View full GKSL stock details →

📡 Get AI alerts when GKSL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GKSL — Free

📊 More GKSL filings

See all GKSL filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GKSL files new disclosures

Track GKSL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GKSL — Free

Free account · 2 AI queries/day